Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock

GlobeNewswire November 25, 2022

First Wave BioPharma, Inc. Announces Closing of Private Placement

GlobeNewswire November 22, 2022

First Wave BioPharma, Inc. Announces Private Placement

GlobeNewswire November 21, 2022

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

GlobeNewswire November 16, 2022

First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation

GlobeNewswire October 31, 2022

First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering

GlobeNewswire October 11, 2022

First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

GlobeNewswire October 10, 2022

First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering

GlobeNewswire October 6, 2022

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc.

Accesswire October 6, 2022

First Wave BioPharma's CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

GlobeNewswire September 28, 2022

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

GlobeNewswire September 19, 2022

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference

GlobeNewswire September 14, 2022

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

GlobeNewswire September 7, 2022

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

GlobeNewswire August 31, 2022

First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

GlobeNewswire August 29, 2022

First Wave BioPharma, Inc. Announces Reverse Stock Split

GlobeNewswire August 25, 2022

First Wave BioPharma, Inc. Announces Private Placement

GlobeNewswire July 15, 2022

First Wave BioPharma to Participate in "Fireside Chat" at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

GlobeNewswire April 29, 2022

First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio

GlobeNewswire April 27, 2022